Product: MSR1 Antibody
Catalog: DF6694
Description: Rabbit polyclonal antibody to MSR1
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Xenopus
Mol.Wt.: 50kDa; 50kD(Calculated).
Uniprot: P21757
RRID: AB_2838656

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(92%), Bovine(83%), Horse(100%), Sheep(83%), Rabbit(92%), Dog(83%), Xenopus(80%)
Clonality:
Polyclonal
Specificity:
MSR1 Antibody detects endogenous levels of total MSR1.
RRID:
AB_2838656
Cite Format: Affinity Biosciences Cat# DF6694, RRID:AB_2838656.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CD204; CD204 antigen; CD24; Macrophage acetylated LDL receptor I and II; Macrophage scavenger receptor 1; Macrophage scavenger receptor type III; Macrophage scavenger receptor types I and II; Msr 1; MSR1; MSRE_HUMAN; phSR1; phSR2; SCARA 1; SCARA1; Scavenger receptor class A member 1; Scavenger receptor class A, member 1; Scavenger receptor type A; Scvr; SR A; SRA;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P21757 MSRE_HUMAN:

Isoform I, isoform II and isoform III are expressed in monocyte-derived macrophages. Isoform I and isoform II are expressed in the liver, placenta and brain.

Description:
This gene encodes the class A macrophage scavenger receptors, which include three different types (1, 2, 3) generated by alternative splicing of this gene. These receptors or isoforms are macrophage-specific trimeric integral membrane glycoproteins and have been implicated in many macrophage-associated physiological and pathological processes including atherosclerosis, Alzheimer's disease, and host defense. The isoforms type 1 and type 2 are functional receptors and are able to mediate the endocytosis of modified low density lipoproteins (LDLs). The isoform type 3 does not internalize modified LDL (acetyl-LDL) despite having the domain shown to mediate this function in the types 1 and 2 isoforms. It has an altered intracellular processing and is trapped within the endoplasmic reticulum, making it unable to perform endocytosis. The isoform type 3 can inhibit the function of isoforms type 1 and type 2 when co-expressed, indicating a dominant negative effect and suggesting a mechanism for regulation of scavenger receptor activity in macrophages. [provided by RefSeq, Jul 2008]
Sequence:
MEQWDHFHNQQEDTDSCSESVKFDARSMTALLPPNPKNSPSLQEKLKSFKAALIALYLLVFAVLIPLIGIVAAQLLKWETKNCSVSSTNANDITQSLTGKGNDSEEEMRFQEVFMEHMSNMEKRIQHILDMEANLMDTEHFQNFSMTTDQRFNDILLQLSTLFSSVQGHGNAIDEISKSLISLNTTLLDLQLNIENLNGKIQENTFKQQEEISKLEERVYNVSAEIMAMKEEQVHLEQEIKGEVKVLNNITNDLRLKDWEHSQTLRNITLIQGPPGPPGEKGDRGPTGESGPRGFPGPIGPPGLKGDRGAIGFPGSRGLPGYAGRPGNSGPKGQKGEKGSGNTLTPFTKVRLVGGSGPHEGRVEILHSGQWGTICDDRWEVRVGQVVCRSLGYPGVQAVHKAAHFGQGTGPIWLNEVFCFGRESSIEECKIRQWGTRACSHSEDAGVTCTL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Pig
92
Rabbit
92
Bovine
83
Sheep
83
Dog
83
Xenopus
80
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P21757 As Substrate

Site PTM Type Enzyme
T14 Phosphorylation
S16 Phosphorylation
S18 Phosphorylation
S27 Phosphorylation
T29 Phosphorylation
N221 N-Glycosylation
K245 Methylation
T251 Phosphorylation

Research Backgrounds

Function:

Membrane glycoproteins implicated in the pathologic deposition of cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. These receptors mediate the endocytosis of a diverse group of macromolecules, including modified low density lipoproteins (LDL). Isoform III does not internalize acetylated LDL.

Subcellular Location:

Membrane>Single-pass type II membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Isoform I, isoform II and isoform III are expressed in monocyte-derived macrophages. Isoform I and isoform II are expressed in the liver, placenta and brain.

Subunit Structure:

Homotrimer (By similarity). Interacts with MYO18A.

Research Fields

· Cellular Processes > Transport and catabolism > Phagosome.   (View pathway)

References

1). Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-A on activated macrophages to treat rheumatoid arthritis. Biomaterials (PubMed: 32781326) [IF=14.0]

Application: IF/ICC    Species: mouse    Sample: Raw264.7 cells

Fig. 2. PAB targets SR-A in vitro. (a) Flow cytometry analysis showing uptake of DiD-BSA NPs and DiD-PAB NPs in Raw264.7 cells and LPS-AR. (b) LPS-AR were pretreated with various inhibitors of endocytic pathways, then measured for cellular uptake of DiD-BSA NPs and (c) DiD-PAB NPs. (d) Levels of SR-A on the surface of various cell types was determined using flow cytometry. (e–f) Quantitation of fluorescence intensity as a measure of NPs uptake in various cells. (g) LPS-AR were pretreated with BSA or PAB, and cellular uptake of DiD-BSA NPs and DiD-PAB NPs was measured. (h) Confocal micrographs showing co-localization of NPs (red) with SR-A (green). Cell nuclei were stained with DAPI (blue), Red: DiD, Green: SR-A. Scale bar: 10 μm. All results are shown as mean ± SD, n = 5. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Raw264.7 group in Fig. 2d and f. Abbreviations: NT, non-pretreatment group; LPS-AR, LPS-activated Raw264.7 cells; IFN-γ-AR-60 ng, 60 ng/mL IFN-γ activated Raw264.7 cells; IFN-γ-AR-80 ng, 80 ng/mL IFN-γ activated Raw264.7 cells; IL-4-AR, IL-4-activated macrophages. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

2). Three polymethoxyflavones from the peel of Citrus reticulata “Chachi” inhibits oxidized low-density lipoprotein-induced macrophage-derived foam cell formation. Frontiers in Cardiovascular Medicine (PubMed: 35966555) [IF=3.6]

Application: WB    Species: Mice    Sample: RAW264.7 cells

FIGURE 5 Effects of TAN, HxMF, and HpMF on mRNA expression of SRA1 in ox-LDL-treated RAW264.7 cells (A); effects of TAN, HxMF, and HpMF on mRNA expression of CD36 in ox-LDL-treated RAW264.7 cells (B); effects of TAN on SRA1 and CD36 protein expression in ox- LDL-treated RAW264.7 cells (C1,C2); effects of HxMF on SRA1 and CD36 protein expression in ox-LDL-treated RAW264.7 cells (D1,D2); and effects of HpMF on SRA1 and CD36 protein expression in ox-LDL-treated RAW264.7 cells (E1,E2). All experiments were run in triplicate, and data showed mean ± SD. ##p < 0.01 compared with the control group, *p < 0.05 and **p < 0.01 compared with the ox-LDL group.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.